Clinical Trials Browser

Phase 2/3 × Multiple Myeloma × 90 days × Clear all

NCT07095452 2026-03-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

660 enrolled

Plasma cell

Multiple Myeloma

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

30 enrolled

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT07428369 2026-02-23

LINKER-MM8

Phase 2/3 Not yet recruiting

1,570 enrolled

Plasma cell

Multiple Myeloma

NCT07319897 2026-01-06

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

Phase 2/3 Not yet recruiting

300 enrolled

Plasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell